Early data about the use of roflumilast in patients with COPD

Dimitrios Patoulias, Maria-Styliani Kalogirou, Eleni Papakonstantinou


Roflumilast is a new second line anti-inflammatory drug, approved by the FDA in March 2011, for the treatment of patients with a specific phenotype of Chronic Obstructive Pulmonary Disease (COPD). In this review article, after systematically reviewing the latest published references on roflumilast, we aim at presenting the experimental and clinical results that have emerged so far, concerning the benefits and the limitations of its use and the future prospects for the optimization of its effects.


roflumilast, COPD, chronic bronchitis, exacerbation, anti-inflammatory

Full Text:



  • There are currently no refbacks.